Product Pathways - Tyrosine Kinase / Adaptors
Phospho-ALK (Tyr1586) (3B4) Rabbit mAb #3348
|3348S||100 µl (10 western blots)||---||In Stock||---|
|3348||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
|W||1:1000||Human||Endogenous||80 (NPM-ALK) 220 (ALK)||Rabbit IgG|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting
Species predicted to react based on 100% sequence homology: Mouse.
Specificity / Sensitivity
Phospho-ALK (Tyr1586) (3B4) Rabbit mAb detects ALK only when phosphorylated at Tyr1586 (equivalent to Tyr646 of NPM-ALK). This antibody may cross-react with other activated protein tyrosine kinases including EGFR.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr1586 of human ALK.
Western blot analysis of Sup-M2 cell lysate, using Phospho-ALK (Tyr1586) (3B4) Rabbit mAb (A and B), and ALK Antibody (C and D).The phospho-specificity of this antibody was characterized by treating the membrane with calf intestinal alkaline phosphatase (CIP) (B and D) after Western transfer.
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor for pleiotrophin (PTN), a growth factor involved in embryonic brain development (1-3). In ALK-expressing cells, PTN induces phosphorylation of both ALK and the downstream effectors IRS-1, Shc, PLCγ, and PI3 kinase (1). ALK was originally discovered as a nucleophosmin (NPM)-ALK fusion protein produced by a translocation (4). Investigators have found that the NPM-ALK fusion protein is a constitutively active, oncogenic tyrosine kinase associated with anaplastic lymphoma (4). Research literature suggests that activation of PLCγ by NPM-ALK may be a crucial step for its mitogenic activity and involved in the pathogenesis of anaplastic lymphomas (5).
A distinct ALK oncogenic fusion protein involving ALK and echinoderm microtubule-associated protein like 4 (EML4) has been described in the research literature from a non-small cell lung cancer (NSCLC) cell line, with corresponding fusion transcripts present in some cases of lung adenocarcinoma. The short, amino-terminal region of the microtubule-associated protein EML4 is fused to the kinase domain of ALK (6-8).
- Stoica, G.E. et al. (2001) J Biol Chem 276, 16772-9.
- Iwahara, T. et al. (1997) Oncogene 14, 439-49.
- Morris, S.W. et al. (1997) Oncogene 14, 2175-88.
- Morris, S.W. et al. (1994) Science 263, 1281-4.
- Bai, R.Y. et al. (1998) Mol Cell Biol 18, 6951-61.
- Rikova, K. et al. (2007) Cell 131, 1190-203.
- Takeuchi, K. et al. (2008) Clin Cancer Res 14, 6618-24.
- Soda, M. et al. (2007) Nature 448, 561-6.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 3333 ALK (C26G7) Rabbit mAb
- 3341 Phospho-ALK (Tyr1604) Antibody
- 3343 Phospho-ALK (Tyr1586) Antibody
- 3710 Phospho-ALK (Tyr1278) Antibody
- 3714 Phospho-ALK (Tyr1282/1283) Antibody
- 7071 Phototope®-HRP Western Blot Detection System, Anti-rabbit IgG, HRP-linked Antibody
- 7074 Anti-rabbit IgG, HRP-linked Antibody
- 7720 Prestained Protein Marker, Broad Range (Premixed Format)
- 7727 Biotinylated Protein Ladder Detection Pack
- 7003 20X LumiGLO® Reagent and 20X Peroxide
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
This antibody is developed, validated, and produced by CST using in part technology under license (granting certain rights including those under U.S. Patents No. 5,675,063 and 7,429,487) from Epitomics, Inc.